Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and route of administration
Local delivery of RJVA-001 achieved therapeutically relevant GLP-1 expression within pancreatic beta cells with no adverse safety effects observed
Company plans to initiate first-in-human studies with RJVA-001 in first half of 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more